HARMONi-6 Generates Enthusiasm as a Potential New Option for Squamous NSCLC
Key Points
- HARMONi-6 demonstrated a significant overall survival benefit with ivonescimab plus chemotherapy in treatment-naïve patients with advanced squamous non-small cell lung cancer (NSCLC).
- The panel viewed the results as particularly important because the study improved outcomes compared with an active immunotherapy-based standard rather than chemotherapy alone.
- Questions regarding global applicability, patient selection, and VEGF-related toxicities remain, with HARMONi-3 expected to provide additional clarity.
Benjamin P. Levy, MD, of Johns Hopkins Sidney Kimmel Cancer Center, was joined by Jarushka Naidoo, MB, BCh, MHS, of Beaumont RCSI Cancer Centre, and Bo Wang, MD, of Willamette Valley Cancer Institute and Research Center, for a discussion of the phase 3 HARMONi-6 trial presented at the 2026 American Society of Clinical Oncology Annual Meeting.
The study evaluated ivonescimab, a novel bispecific antibody targeting both PD-1 and VEGF, in combination with chemotherapy for treatment-naïve patients with advanced squamous NSCLC. The panel reviewed the trial design, patient population, and key efficacy and safety findings, highlighting the significance of a positive phase 3 study in a disease setting that has experienced relatively few therapeutic advances compared with adenocarcinoma.
The panel agreed that the most notable finding was the significant overall survival (OS) improvement observed with ivonescimab plus chemotherapy compared with chemotherapy and tislelizumab.
Dr. Wang emphasized that demonstrating a survival advantage against an active immunotherapy-based comparator represents a meaningful achievement, particularly in a patient population that remains difficult to treat. Dr. Naidoo noted that squamous NSCLC continues to be an area of substantial unmet need despite advances in precision medicine and immunotherapy, making the positive results particularly noteworthy.
While the OS analysis was conducted at an interim time point, the panel viewed the findings as highly encouraging and indicative of the potential value of dual PD-1 and VEGF inhibition.